ResMed Inc. (RMD)
Is Resmed Stock the Right Pick for Your Portfolio Now?
RMD expands mask and device sales while maintaining strong liquidity, but macro and competitive pressures loom.
After Plunging 8.7% in 4 Weeks, Here's Why the Trend Might Reverse for ResMed (RMD)
The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Aquatic Capital Management LLC Buys 12,642 Shares of ResMed Inc. $RMD
Aquatic Capital Management LLC raised its stake in ResMed Inc. (NYSE: RMD) by 106.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,564 shares of the medical equipment provider's stock after acquiring an additional 12,642 shares during the quarter. Aquatic
ResMed At $250: Missed Opportunity Or A Trap In The Making?
ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a company that is demonstrating reasonable growth, maintaining solid cash flow and margin, has a low-debt capital structure, and is fairly valued.
RMD Stock Up Following Q2 Earnings & Revenue Beat, Margins Expand
Resmed shares rise after Q2 EPS and revenues beat expectations, with the gross and operating margins expanding sharply across core segments.
ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell
ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell
ResMed Inc. (RMD) Q2 2026 Earnings Call Transcript
ResMed Inc. (RMD) Q2 2026 Earnings Call Transcript
ResMed (RMD) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ResMed (RMD) Q2 Earnings and Revenues Beat Estimates
ResMed (RMD) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.43 per share a year ago.
Here's Why ResMed (RMD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are Medical Stocks Lagging ResMed (RMD) This Year?
Here is how ResMed (RMD) and Compass Therapeutics, Inc. (CMPX) have performed compared to their sector so far this year.
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
